O-desmethyltramadol - Syntrix Biosystems

Drug Profile

O-desmethyltramadol - Syntrix Biosystems

Alternative Names: O-DSMT; Omnitram

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Syntrix Biosystems
  • Class Cyclohexanols; Dimethylamines; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 20 Oct 2017 Syntrix Biosystems plans a phase Ib trial for Pain (In volunteers) in USA in October 2017 (NCT03312777)
  • 29 Apr 2016 Phase-I development is ongoing in USA
  • 01 Oct 2014 Syntrix completes a phase I trial in Pain (In volunteers) in Japan (NCT02205554)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top